nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—FDPS—prostate gland—urinary bladder cancer	0.0231	0.19	CbGeAlD
Ibandronate—FDPS—seminal vesicle—urinary bladder cancer	0.0195	0.161	CbGeAlD
Ibandronate—FDPS—smooth muscle tissue—urinary bladder cancer	0.0164	0.135	CbGeAlD
Ibandronate—FDPS—renal system—urinary bladder cancer	0.0157	0.13	CbGeAlD
Ibandronate—FDPS—urethra—urinary bladder cancer	0.0155	0.127	CbGeAlD
Ibandronate—FDPS—female reproductive system—urinary bladder cancer	0.0126	0.104	CbGeAlD
Ibandronate—FDPS—vagina—urinary bladder cancer	0.0114	0.0938	CbGeAlD
Ibandronate—FDPS—lymph node—urinary bladder cancer	0.00738	0.0607	CbGeAlD
Ibandronate—Risedronate—PTGS2—urinary bladder cancer	0.00343	1	CrCbGaD
Ibandronate—Pneumonia—Epirubicin—urinary bladder cancer	0.000675	0.000772	CcSEcCtD
Ibandronate—Infestation NOS—Epirubicin—urinary bladder cancer	0.000672	0.000768	CcSEcCtD
Ibandronate—Infestation—Epirubicin—urinary bladder cancer	0.000672	0.000768	CcSEcCtD
Ibandronate—Rash—Thiotepa—urinary bladder cancer	0.000671	0.000767	CcSEcCtD
Ibandronate—Bronchitis—Doxorubicin—urinary bladder cancer	0.00067	0.000766	CcSEcCtD
Ibandronate—Dermatitis—Thiotepa—urinary bladder cancer	0.00067	0.000766	CcSEcCtD
Ibandronate—Headache—Thiotepa—urinary bladder cancer	0.000666	0.000762	CcSEcCtD
Ibandronate—Decreased appetite—Etoposide—urinary bladder cancer	0.000664	0.000759	CcSEcCtD
Ibandronate—Renal failure—Epirubicin—urinary bladder cancer	0.00066	0.000754	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00066	0.000754	CcSEcCtD
Ibandronate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000659	0.000754	CcSEcCtD
Ibandronate—Fatigue—Etoposide—urinary bladder cancer	0.000659	0.000753	CcSEcCtD
Ibandronate—Stomatitis—Epirubicin—urinary bladder cancer	0.000655	0.000748	CcSEcCtD
Ibandronate—Constipation—Etoposide—urinary bladder cancer	0.000653	0.000747	CcSEcCtD
Ibandronate—Pain—Etoposide—urinary bladder cancer	0.000653	0.000747	CcSEcCtD
Ibandronate—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000653	0.000746	CcSEcCtD
Ibandronate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000648	0.000741	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000648	0.00074	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—urinary bladder cancer	0.000647	0.00074	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—urinary bladder cancer	0.000644	0.000736	CcSEcCtD
Ibandronate—Sweating—Epirubicin—urinary bladder cancer	0.000644	0.000736	CcSEcCtD
Ibandronate—Asthenia—Gemcitabine—urinary bladder cancer	0.000642	0.000734	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—urinary bladder cancer	0.000639	0.000731	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000636	0.000727	CcSEcCtD
Ibandronate—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000635	0.000726	CcSEcCtD
Ibandronate—Pruritus—Gemcitabine—urinary bladder cancer	0.000633	0.000724	CcSEcCtD
Ibandronate—Nausea—Thiotepa—urinary bladder cancer	0.000632	0.000722	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—urinary bladder cancer	0.000632	0.000722	CcSEcCtD
Ibandronate—Weight decreased—Doxorubicin—urinary bladder cancer	0.000631	0.000721	CcSEcCtD
Ibandronate—Feeling abnormal—Etoposide—urinary bladder cancer	0.00063	0.00072	CcSEcCtD
Ibandronate—Pneumonia—Doxorubicin—urinary bladder cancer	0.000625	0.000714	CcSEcCtD
Ibandronate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000625	0.000714	CcSEcCtD
Ibandronate—Pruritus—Fluorouracil—urinary bladder cancer	0.000622	0.000711	CcSEcCtD
Ibandronate—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000621	0.00071	CcSEcCtD
Ibandronate—Infestation—Doxorubicin—urinary bladder cancer	0.000621	0.00071	CcSEcCtD
Ibandronate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000615	0.000702	CcSEcCtD
Ibandronate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000612	0.0007	CcSEcCtD
Ibandronate—Renal failure—Doxorubicin—urinary bladder cancer	0.000611	0.000698	CcSEcCtD
Ibandronate—Urticaria—Etoposide—urinary bladder cancer	0.000607	0.000694	CcSEcCtD
Ibandronate—Haemoglobin—Epirubicin—urinary bladder cancer	0.000606	0.000693	CcSEcCtD
Ibandronate—Stomatitis—Doxorubicin—urinary bladder cancer	0.000606	0.000692	CcSEcCtD
Ibandronate—Abdominal pain—Etoposide—urinary bladder cancer	0.000604	0.00069	CcSEcCtD
Ibandronate—Body temperature increased—Etoposide—urinary bladder cancer	0.000604	0.00069	CcSEcCtD
Ibandronate—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000604	0.00069	CcSEcCtD
Ibandronate—Haemorrhage—Epirubicin—urinary bladder cancer	0.000603	0.000689	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—urinary bladder cancer	0.000602	0.000688	CcSEcCtD
Ibandronate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000602	0.000688	CcSEcCtD
Ibandronate—Asthenia—Cisplatin—urinary bladder cancer	0.000598	0.000684	CcSEcCtD
Ibandronate—Pharyngitis—Epirubicin—urinary bladder cancer	0.000598	0.000684	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000598	0.000683	CcSEcCtD
Ibandronate—Sweating—Doxorubicin—urinary bladder cancer	0.000596	0.000681	CcSEcCtD
Ibandronate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000595	0.00068	CcSEcCtD
Ibandronate—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000594	0.000679	CcSEcCtD
Ibandronate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000592	0.000677	CcSEcCtD
Ibandronate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000591	0.000675	CcSEcCtD
Ibandronate—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000588	0.000672	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—urinary bladder cancer	0.000584	0.000668	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000582	0.000665	CcSEcCtD
Ibandronate—Dizziness—Fluorouracil—urinary bladder cancer	0.000582	0.000665	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000581	0.000664	CcSEcCtD
Ibandronate—Chills—Methotrexate—urinary bladder cancer	0.000578	0.000661	CcSEcCtD
Ibandronate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000571	0.000652	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—urinary bladder cancer	0.000569	0.000651	CcSEcCtD
Ibandronate—Vomiting—Gemcitabine—urinary bladder cancer	0.000569	0.00065	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—urinary bladder cancer	0.000564	0.000645	CcSEcCtD
Ibandronate—Rash—Gemcitabine—urinary bladder cancer	0.000564	0.000645	CcSEcCtD
Ibandronate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000564	0.000644	CcSEcCtD
Ibandronate—Eye disorder—Epirubicin—urinary bladder cancer	0.000563	0.000644	CcSEcCtD
Ibandronate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000563	0.000643	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—urinary bladder cancer	0.000561	0.000641	CcSEcCtD
Ibandronate—Erythema—Methotrexate—urinary bladder cancer	0.000561	0.000641	CcSEcCtD
Ibandronate—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000561	0.000641	CcSEcCtD
Ibandronate—Headache—Gemcitabine—urinary bladder cancer	0.000561	0.000641	CcSEcCtD
Ibandronate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00056	0.000639	CcSEcCtD
Ibandronate—Vomiting—Fluorouracil—urinary bladder cancer	0.000559	0.000639	CcSEcCtD
Ibandronate—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000558	0.000638	CcSEcCtD
Ibandronate—Rash—Fluorouracil—urinary bladder cancer	0.000555	0.000634	CcSEcCtD
Ibandronate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000554	0.000633	CcSEcCtD
Ibandronate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000554	0.000633	CcSEcCtD
Ibandronate—Headache—Fluorouracil—urinary bladder cancer	0.000551	0.00063	CcSEcCtD
Ibandronate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000551	0.00063	CcSEcCtD
Ibandronate—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00055	0.000628	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000549	0.000628	CcSEcCtD
Ibandronate—Asthenia—Etoposide—urinary bladder cancer	0.000548	0.000627	CcSEcCtD
Ibandronate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000548	0.000626	CcSEcCtD
Ibandronate—Angiopathy—Epirubicin—urinary bladder cancer	0.000547	0.000625	CcSEcCtD
Ibandronate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000547	0.000625	CcSEcCtD
Ibandronate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000545	0.000622	CcSEcCtD
Ibandronate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000543	0.000621	CcSEcCtD
Ibandronate—Back pain—Methotrexate—urinary bladder cancer	0.000542	0.00062	CcSEcCtD
Ibandronate—Chills—Epirubicin—urinary bladder cancer	0.000541	0.000618	CcSEcCtD
Ibandronate—Pruritus—Etoposide—urinary bladder cancer	0.000541	0.000618	CcSEcCtD
Ibandronate—Alopecia—Epirubicin—urinary bladder cancer	0.000533	0.000609	CcSEcCtD
Ibandronate—Nausea—Gemcitabine—urinary bladder cancer	0.000532	0.000607	CcSEcCtD
Ibandronate—Vomiting—Cisplatin—urinary bladder cancer	0.00053	0.000606	CcSEcCtD
Ibandronate—Mental disorder—Epirubicin—urinary bladder cancer	0.000528	0.000604	CcSEcCtD
Ibandronate—Rash—Cisplatin—urinary bladder cancer	0.000526	0.000601	CcSEcCtD
Ibandronate—Dermatitis—Cisplatin—urinary bladder cancer	0.000525	0.0006	CcSEcCtD
Ibandronate—Malnutrition—Epirubicin—urinary bladder cancer	0.000525	0.0006	CcSEcCtD
Ibandronate—Erythema—Epirubicin—urinary bladder cancer	0.000525	0.0006	CcSEcCtD
Ibandronate—Diarrhoea—Etoposide—urinary bladder cancer	0.000523	0.000598	CcSEcCtD
Ibandronate—Nausea—Fluorouracil—urinary bladder cancer	0.000523	0.000597	CcSEcCtD
Ibandronate—Eye disorder—Doxorubicin—urinary bladder cancer	0.000521	0.000596	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00052	0.000595	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—urinary bladder cancer	0.000518	0.000592	CcSEcCtD
Ibandronate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000518	0.000592	CcSEcCtD
Ibandronate—Flatulence—Epirubicin—urinary bladder cancer	0.000517	0.000591	CcSEcCtD
Ibandronate—Dysgeusia—Epirubicin—urinary bladder cancer	0.000514	0.000587	CcSEcCtD
Ibandronate—Back pain—Epirubicin—urinary bladder cancer	0.000508	0.00058	CcSEcCtD
Ibandronate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000506	0.000578	CcSEcCtD
Ibandronate—Malaise—Methotrexate—urinary bladder cancer	0.000506	0.000578	CcSEcCtD
Ibandronate—Dizziness—Etoposide—urinary bladder cancer	0.000505	0.000577	CcSEcCtD
Ibandronate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000505	0.000577	CcSEcCtD
Ibandronate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000504	0.000576	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—urinary bladder cancer	0.000504	0.000576	CcSEcCtD
Ibandronate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000503	0.000575	CcSEcCtD
Ibandronate—Chills—Doxorubicin—urinary bladder cancer	0.000501	0.000572	CcSEcCtD
Ibandronate—Nausea—Cisplatin—urinary bladder cancer	0.000495	0.000566	CcSEcCtD
Ibandronate—Alopecia—Doxorubicin—urinary bladder cancer	0.000493	0.000563	CcSEcCtD
Ibandronate—Mental disorder—Doxorubicin—urinary bladder cancer	0.000489	0.000559	CcSEcCtD
Ibandronate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000487	0.000557	CcSEcCtD
Ibandronate—Vomiting—Etoposide—urinary bladder cancer	0.000486	0.000555	CcSEcCtD
Ibandronate—Erythema—Doxorubicin—urinary bladder cancer	0.000486	0.000555	CcSEcCtD
Ibandronate—Malnutrition—Doxorubicin—urinary bladder cancer	0.000486	0.000555	CcSEcCtD
Ibandronate—Anaemia—Epirubicin—urinary bladder cancer	0.000485	0.000554	CcSEcCtD
Ibandronate—Rash—Etoposide—urinary bladder cancer	0.000482	0.000551	CcSEcCtD
Ibandronate—Dermatitis—Etoposide—urinary bladder cancer	0.000481	0.00055	CcSEcCtD
Ibandronate—Headache—Etoposide—urinary bladder cancer	0.000479	0.000547	CcSEcCtD
Ibandronate—Flatulence—Doxorubicin—urinary bladder cancer	0.000479	0.000547	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—urinary bladder cancer	0.000477	0.000546	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—urinary bladder cancer	0.000477	0.000546	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—urinary bladder cancer	0.000477	0.000546	CcSEcCtD
Ibandronate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000476	0.000543	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000474	0.000542	CcSEcCtD
Ibandronate—Malaise—Epirubicin—urinary bladder cancer	0.000473	0.000541	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—urinary bladder cancer	0.000472	0.000539	CcSEcCtD
Ibandronate—Vertigo—Epirubicin—urinary bladder cancer	0.000472	0.000539	CcSEcCtD
Ibandronate—Back pain—Doxorubicin—urinary bladder cancer	0.00047	0.000537	CcSEcCtD
Ibandronate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000467	0.000534	CcSEcCtD
Ibandronate—Palpitations—Epirubicin—urinary bladder cancer	0.000464	0.00053	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000458	0.000523	CcSEcCtD
Ibandronate—Infection—Methotrexate—urinary bladder cancer	0.000455	0.00052	CcSEcCtD
Ibandronate—Nausea—Etoposide—urinary bladder cancer	0.000454	0.000519	CcSEcCtD
Ibandronate—Hypertension—Epirubicin—urinary bladder cancer	0.000453	0.000518	CcSEcCtD
Ibandronate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000451	0.000515	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000449	0.000513	CcSEcCtD
Ibandronate—Anaemia—Doxorubicin—urinary bladder cancer	0.000449	0.000513	CcSEcCtD
Ibandronate—Chest pain—Epirubicin—urinary bladder cancer	0.000447	0.000511	CcSEcCtD
Ibandronate—Arthralgia—Epirubicin—urinary bladder cancer	0.000447	0.000511	CcSEcCtD
Ibandronate—Myalgia—Epirubicin—urinary bladder cancer	0.000447	0.000511	CcSEcCtD
Ibandronate—Anxiety—Epirubicin—urinary bladder cancer	0.000445	0.000509	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—urinary bladder cancer	0.000445	0.000508	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000444	0.000507	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000442	0.000506	CcSEcCtD
Ibandronate—Discomfort—Epirubicin—urinary bladder cancer	0.000441	0.000505	CcSEcCtD
Ibandronate—Malaise—Doxorubicin—urinary bladder cancer	0.000438	0.0005	CcSEcCtD
Ibandronate—Dry mouth—Epirubicin—urinary bladder cancer	0.000437	0.000499	CcSEcCtD
Ibandronate—Vertigo—Doxorubicin—urinary bladder cancer	0.000436	0.000499	CcSEcCtD
Ibandronate—Palpitations—Doxorubicin—urinary bladder cancer	0.000429	0.00049	CcSEcCtD
Ibandronate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000428	0.00049	CcSEcCtD
Ibandronate—Infection—Epirubicin—urinary bladder cancer	0.000426	0.000486	CcSEcCtD
Ibandronate—Shock—Epirubicin—urinary bladder cancer	0.000421	0.000482	CcSEcCtD
Ibandronate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00042	0.00048	CcSEcCtD
Ibandronate—Hypertension—Doxorubicin—urinary bladder cancer	0.000419	0.000479	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000417	0.000477	CcSEcCtD
Ibandronate—Skin disorder—Epirubicin—urinary bladder cancer	0.000416	0.000475	CcSEcCtD
Ibandronate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000414	0.000473	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—urinary bladder cancer	0.000414	0.000473	CcSEcCtD
Ibandronate—Chest pain—Doxorubicin—urinary bladder cancer	0.000413	0.000472	CcSEcCtD
Ibandronate—Myalgia—Doxorubicin—urinary bladder cancer	0.000413	0.000472	CcSEcCtD
Ibandronate—Arthralgia—Doxorubicin—urinary bladder cancer	0.000413	0.000472	CcSEcCtD
Ibandronate—Anxiety—Doxorubicin—urinary bladder cancer	0.000412	0.000471	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—urinary bladder cancer	0.000411	0.00047	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000411	0.000469	CcSEcCtD
Ibandronate—Discomfort—Doxorubicin—urinary bladder cancer	0.000408	0.000467	CcSEcCtD
Ibandronate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000404	0.000462	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000403	0.00046	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000398	0.000455	CcSEcCtD
Ibandronate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000396	0.000453	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000395	0.000452	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—urinary bladder cancer	0.000395	0.000451	CcSEcCtD
Ibandronate—Infection—Doxorubicin—urinary bladder cancer	0.000394	0.00045	CcSEcCtD
Ibandronate—Pain—Methotrexate—urinary bladder cancer	0.000391	0.000447	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00039	0.000446	CcSEcCtD
Ibandronate—Shock—Doxorubicin—urinary bladder cancer	0.00039	0.000446	CcSEcCtD
Ibandronate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000389	0.000444	CcSEcCtD
Ibandronate—Insomnia—Epirubicin—urinary bladder cancer	0.000387	0.000443	CcSEcCtD
Ibandronate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000385	0.00044	CcSEcCtD
Ibandronate—Paraesthesia—Epirubicin—urinary bladder cancer	0.000385	0.00044	CcSEcCtD
Ibandronate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000383	0.000438	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000377	0.000431	CcSEcCtD
Ibandronate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000377	0.000431	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000374	0.000428	CcSEcCtD
Ibandronate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000372	0.000426	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00037	0.000423	CcSEcCtD
Ibandronate—Fatigue—Epirubicin—urinary bladder cancer	0.000369	0.000422	CcSEcCtD
Ibandronate—Pain—Epirubicin—urinary bladder cancer	0.000366	0.000419	CcSEcCtD
Ibandronate—Constipation—Epirubicin—urinary bladder cancer	0.000366	0.000419	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—urinary bladder cancer	0.000364	0.000416	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000362	0.000414	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000362	0.000414	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000361	0.000413	CcSEcCtD
Ibandronate—Insomnia—Doxorubicin—urinary bladder cancer	0.000358	0.00041	CcSEcCtD
Ibandronate—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000356	0.000407	CcSEcCtD
Ibandronate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000353	0.000403	CcSEcCtD
Ibandronate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00035	0.0004	CcSEcCtD
Ibandronate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000349	0.000399	CcSEcCtD
Ibandronate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000345	0.000394	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000342	0.000391	CcSEcCtD
Ibandronate—Fatigue—Doxorubicin—urinary bladder cancer	0.000342	0.000391	CcSEcCtD
Ibandronate—Urticaria—Epirubicin—urinary bladder cancer	0.00034	0.000389	CcSEcCtD
Ibandronate—Pain—Doxorubicin—urinary bladder cancer	0.000339	0.000387	CcSEcCtD
Ibandronate—Constipation—Doxorubicin—urinary bladder cancer	0.000339	0.000387	CcSEcCtD
Ibandronate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000339	0.000387	CcSEcCtD
Ibandronate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000339	0.000387	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000337	0.000385	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—urinary bladder cancer	0.000328	0.000375	CcSEcCtD
Ibandronate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000327	0.000373	CcSEcCtD
Ibandronate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000324	0.00037	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—urinary bladder cancer	0.000324	0.00037	CcSEcCtD
Ibandronate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000316	0.000361	CcSEcCtD
Ibandronate—Urticaria—Doxorubicin—urinary bladder cancer	0.000315	0.00036	CcSEcCtD
Ibandronate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000313	0.000358	CcSEcCtD
Ibandronate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000313	0.000358	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000313	0.000358	CcSEcCtD
Ibandronate—Asthenia—Epirubicin—urinary bladder cancer	0.000307	0.000351	CcSEcCtD
Ibandronate—Pruritus—Epirubicin—urinary bladder cancer	0.000303	0.000346	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—urinary bladder cancer	0.000303	0.000346	CcSEcCtD
Ibandronate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000293	0.000335	CcSEcCtD
Ibandronate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000292	0.000334	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—urinary bladder cancer	0.000291	0.000333	CcSEcCtD
Ibandronate—Rash—Methotrexate—urinary bladder cancer	0.000289	0.00033	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—urinary bladder cancer	0.000288	0.00033	CcSEcCtD
Ibandronate—Headache—Methotrexate—urinary bladder cancer	0.000287	0.000328	CcSEcCtD
Ibandronate—Asthenia—Doxorubicin—urinary bladder cancer	0.000284	0.000325	CcSEcCtD
Ibandronate—Dizziness—Epirubicin—urinary bladder cancer	0.000283	0.000324	CcSEcCtD
Ibandronate—Pruritus—Doxorubicin—urinary bladder cancer	0.00028	0.00032	CcSEcCtD
Ibandronate—Vomiting—Epirubicin—urinary bladder cancer	0.000272	0.000311	CcSEcCtD
Ibandronate—Nausea—Methotrexate—urinary bladder cancer	0.000272	0.000311	CcSEcCtD
Ibandronate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000271	0.00031	CcSEcCtD
Ibandronate—Rash—Epirubicin—urinary bladder cancer	0.00027	0.000309	CcSEcCtD
Ibandronate—Dermatitis—Epirubicin—urinary bladder cancer	0.00027	0.000308	CcSEcCtD
Ibandronate—Headache—Epirubicin—urinary bladder cancer	0.000268	0.000307	CcSEcCtD
Ibandronate—Dizziness—Doxorubicin—urinary bladder cancer	0.000262	0.0003	CcSEcCtD
Ibandronate—Nausea—Epirubicin—urinary bladder cancer	0.000254	0.000291	CcSEcCtD
Ibandronate—Vomiting—Doxorubicin—urinary bladder cancer	0.000252	0.000288	CcSEcCtD
Ibandronate—Rash—Doxorubicin—urinary bladder cancer	0.00025	0.000286	CcSEcCtD
Ibandronate—Dermatitis—Doxorubicin—urinary bladder cancer	0.00025	0.000285	CcSEcCtD
Ibandronate—Headache—Doxorubicin—urinary bladder cancer	0.000248	0.000284	CcSEcCtD
Ibandronate—Nausea—Doxorubicin—urinary bladder cancer	0.000235	0.000269	CcSEcCtD
